Shearman & Sterling advised DNB Markets, Jefferies International Limited, and Kempen & Co. in connection with Nordic Nanovector’s capital increase and issuance of ordinary shares.

Nordic Nanovector intends to use the proceeds of the offering for manufacturing development activities for its lead clinical-stage candidate Betalutin®, for a scale-up of its clinical and commercial activities in preparation for a commercial launch of Betalutin®, as well as for general corporate purposes.

Nordic Nanovector is a Norwegian biopharmaceutical company committed to developing and delivering innovative therapies to patients to address major unmet medical needs and advance cancer care, and aspires to become a leader in the development of targeted therapies for hematological cancers.

The team